

Invitation to presentation of Q-linea's Interim report Q1-2022 on May 5, 2022

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company's Interim report for the period January – March 2022 on Thursday May 5, 2022 at 07:30 a.m. CEST.

Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on May 5, 2022, at 13:00 – 14:00 p.m (CEST).

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the interim report followed by a Q&A-session.

To participate, please call any of the following phone numbers from:

SE: +46 8 5055 8352

UK: +44 333 300 9260

US: +1 646 722 4956

Webcast: <https://tv.streamfabriken.com/q-linea-q1-2022>

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB

Anders.Lundin@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

[Invitation to presentation of Q-linea's Interim report Q1-2022 on May 5, 2022](#)